NeuroThera Labs (TSXV: NTLX) has highlighted the expansion of the U.S. intellectual property (IP) portfolio through its ongoing collaboration with Clearmind Medicine (NASDAQ: CMND).
As part of the collaboration, three U.S. patent applications have been published covering novel combinations of lysergic acid diethylamide (LSD), ketamine, and ibogaine with N-acylethanolamines, including palmitoylethanolamide (PEA), NeuroThera’s proprietary technology.
According to NeuroThera, these U.S. patent applications build on previously announced intellectual property generated through the collaboration, including a U.S. patent application covering the combination of MDMA and N-acylethanolamines for potential treatment of PTSD, anxiety and eating disorders.
NeuroThera and Clearmind continue to advance their collaboration, aimed at bringing safer and more effective treatments to market for some of the most common and rapidly growing mental health conditions.
